Showing 21-25 of 34 data studies & next generation registries:
Tackling Rare Diseases With An Arsenal Of Real-World Data

Published February 28, 2020, – written by Kathryn Starzyk, Senior Director, RWE, OM1 Technological innovations have fostered the age of big data in healthcare – and the huge populations amassed afford the ability to mine for key subpopulations — getting down to ever more precise groups of likely responders to therapy, high-risk patients and[…]

From Big Data to Rapid Analytics for Rheumatology – Data Quality, Tools, and Usage

Wednesday, August 14, 2019 Being able to quickly and cost-effectively collect, analyze, and share real-world evidence on a treatment is critical to improving outcomes in rheumatology conditions. Fortunately, advances in data linkage and processing capabilities are enabling greater access to patient journeys via deep, linked clinical data. At the same time, new tools are empowering[…]

OM1 Expands Rheumatology Conditions With Specialized Data For Licensing And Advanced Analytics

BOSTON, April 30, 2019 — OM1, a leading health outcomes, data and technology company today announced that its rheumatology registries, which track hundreds of thousands of patients longitudinally throughout the United States, are now available for direct licensing as well as studies and advanced analytics. The registries include: Rheumatoid Arthritis Systemic Lupus Erythematosus Sjögrens Giant[…]

OM1 Lupus Registry Reaches More Than 25,000 Patients Prospectively Followed With Deep Clinical And Lab Data

OM1 LUPUS REGISTRY REACHES MORE THAN 25,000 PATIENTS PROSPECTIVELY FOLLOWED WITH DEEP CLINICAL AND LAB DATA Ready for collaborations, the registry enables faster, more cost-effective access to research-grade lupus data for better understanding, comparing, and predicting treatment outcomes BOSTON, October 17, 2018 — OM1, a leading health outcomes, registries and technology company creating solutions to[…]

Using Big Data Like Biomarkers to Advance Clinical Development & Commercialization

March 28, 2018 – 2 PM ET What if you could use predictive models like biomarkers to pre-emptively screen and more effectively target patients who are more likely to respond to your drug in trials and in practice? What if you could rapidly answer questions on comparative treatment outcomes and predict those most likely to[…]